

# HSE – Medicines Management Programme (MMP)



The HSE-Medicines Management Programme (MMP) aims to promote safe, effective and cost-effective prescribing in Ireland. Information on our initiatives is available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

## HSE-MMP Preferred Drugs

Therapeutic Area	<input checked="" type="checkbox"/> HSE-MMP Preferred Drug
PPI	<b>Pantoprazole</b>
Statin	<b>Atorvastatin</b>
ACE inhibitor	<b>Ramipril</b>
ARB	<b>Candesartan</b>
Beta blocker	<b>Bisoprolol</b>
Calcium channel blocker	<b>Amlodipine</b>
Oral anticoagulant	<b>Warfarin or Apixaban</b>
SSRI	<b>Sertraline</b>
SNRI	<b>Venlafaxine</b>
Urinary agent	<b>Tolterodine Prolonged-Release</b>

ACE: angiotensin-converting enzyme; ARB: angiotensin-II receptor blocker; PPI: proton pump inhibitor; SNRI: serotonin and noradrenaline reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor

### HSE-MMP Preferred Standard Oral Nutritional Supplements (ONS)

**List A:** Powdered ONS (*Aymes Shake, Aymes Shake Compact, Complian Shake, Ensure Shake, Foodlink Complete/with Fibre, Fresubin Powder Extra, Nutriplete Shake*) and compact & mini drink sip feeds (*Altralpen Compact, Ensure Compact, Fortisip Compact/with Fibre, Fresubin 2Kcal Mini Drink/with Fibre*).

Standard ONS Prescribing Pathway/List for Adults Living in the Community is available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

### HSE-MMP Preferred Blood Glucose Test Strips (BGTS)

The HSE-MMP has identified preferred BGTS with associated meters for adults with type 1 and type 2 diabetes mellitus. This list was updated in December 2021. The HSE-MMP has identified a list of preferred BGTS with associated meters to ensure that there are a variety of options available to patients and prescribers. The HSE-MMP recognises the potential for a reduction in expenditure on BGTS by increased utilisation of preferred BGTS.

Further information including the preferred BGTS list is available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

### Prescribing and Cost Guidance: Dry Eye Syndrome

The HSE-MMP has completed a review of the treatment of dry eye syndrome (DES) and published a Prescribing and Cost Guidance document in December 2021. The guidance document and associated tips and tools recommend first-line preparations based on clinical evidence and cost, and are intended to promote best practice and aid appropriate prescribing for DES.

These documents are available on [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)

### HSE-MMP Managed Access Processes

Reimbursement application systems are in place for a number of medicines through PCRS online services, including:

- **Versatis® (lidocaine) medicated plasters:** indication-based reimbursement approval for post-herpetic neuralgia (PHN) and a managed approach to reimbursement recommendations for off-label use.
- **Entresto® (sacubitril/valsartan) film-coated tablets:** reimbursement is supported for a specific cohort of patients with symptomatic chronic heart failure.

Managed access protocols are in place for a number of medicines; these are available under *Managed Access Protocols* at [www.hse.ie/yourmedicines](http://www.hse.ie/yourmedicines)